Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
2023年11月2日 - 10:15PM
ビジネスワイヤ(英語)
Rallybio Corporation (Nasdaq: RLYB) today announced that an
abstract for the Rallybio Fetal and Neonatal Alloimmune
Thrombocytopenia (FNAIT) natural history study has been accepted
for poster presentation at the upcoming 65th American Society of
Hematology (ASH) Annual Meeting, which will be held December 9-12,
2023, in San Diego, California.
Details of the poster presentation are as follows:
Title: Identifying Pregnancies at Higher Risk for HPA-1a
Alloimmunization and Fetal/Neonatal Alloimmune Thrombocytopenia
(FNAIT): An International, Prospective, Natural History Study
Presenting Author: Emilie Vander Haar, M.D., Weill Cornell
Medicine, New York-Presbyterian Hospital Session Name: 311.
Disorders of Platelet Number or Function: Clinical and
Epidemiological: Poster I Date/Time: Saturday, December 9,
2023, from 5:30 p.m. - 7:30 p.m. PT (8:30 p.m. - 10:30 p.m. ET)
Abstract #: 1224
The abstract is available on the ASH Annual Meeting website.
Following presentation at the meeting, the poster will be
accessible via the Publications and Presentations section of
Rallybio’s website www.rallybio.com.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology
company with a mission to develop and commercialize
life-transforming therapies for patients with severe and rare
diseases. Rallybio has built a broad pipeline of promising product
candidates aimed at addressing diseases with unmet medical need in
areas of maternal fetal health, complement dysregulation,
hematology, and metabolic disorders. The Company has two clinical
stage programs: RLYB212, an anti-HPA-1a antibody for the prevention
of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and
RLYB116, an inhibitor of complement component 5 (C5), with the
potential to treat several diseases of complement dysregulation, as
well as additional programs in preclinical development.
Rallybio is headquartered in New Haven, Connecticut with an
additional facility at the University of Connecticut’s Technology
Incubation Program in Farmington, Connecticut. For more
information, please visit www.rallybio.com and follow us on
LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on our management’s beliefs and assumptions and on currently
available information. All statements, other than statements of
historical facts contained in this press release are
forward-looking statements. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements
concerning results from the FNAIT natural history study, and
expectations regarding the use of such results. The forward-looking
statements in this press release are only predictions and are based
largely on management’s current expectations and projections about
future events and financial trends that management believes may
affect Rallybio’s business, financial condition and results of
operations. These forward-looking statements speak only as of the
date of this press release and are subject to a number of known and
unknown risks, uncertainties and assumptions, including, but not
limited to, our ability to successfully initiate and conduct our
planned clinical studies, including the FNAIT natural history
study, the Phase 1b clinical study for RLYB212, and our planned
Phase 2 and Phase 3 studies, and complete such clinical studies and
obtain results on our expected timelines, or at all, whether our
cash resources will be sufficient to fund our operating expenses
and capital expenditure requirements and whether we will be
successful raising additional capital, our ability to enter into
strategic partnerships or other arrangements, competition from
other biotechnology and pharmaceutical companies, and those risks
and uncertainties described in Rallybio’s filings with the U.S.
Securities and Exchange Commission (SEC), including Rallybio’s
Quarterly Report on Form 10-Q for the period ended June 30, 2023,
and subsequent filings with the SEC. The events and circumstances
reflected in our forward-looking statements may not be achieved or
occur and actual future results, levels of activity, performance
and events and circumstances could differ materially from those
projected in the forward-looking statements. Except as required by
applicable law, we are not obligated to publicly update or revise
any forward-looking statements contained in this press release,
whether as a result of any new information, future events, changed
circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026184173/en/
Investor Contacts Ami Bavishi Head of Investor Relations
and Communications 475-47-RALLY (Ext. 282) abavishi@rallybio.com
Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com Media Contact Jorge Gaeta
Mission North (516) 430-7659 Rallybio@missionnorth.com
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 4 2024 まで 5 2024
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 5 2023 まで 5 2024